| UniProt ID | PCNA_HUMAN | |
|---|---|---|
| UniProt AC | P12004 | |
| Protein Name | Proliferating cell nuclear antigen | |
| Gene Name | PCNA | |
| Organism | Homo sapiens (Human). | |
| Sequence Length | 261 | |
| Subcellular Localization | Nucleus . Colocalizes with CREBBP, EP300 and POLD1 to sites of DNA damage (PubMed:24939902). Forms nuclear foci representing sites of ongoing DNA replication and vary in morphology and number during S phase. Together with APEX2, is redistributed in d | |
| Protein Description | Auxiliary protein of DNA polymerase delta and is involved in the control of eukaryotic DNA replication by increasing the polymerase's processibility during elongation of the leading strand. Induces a robust stimulatory effect on the 3'-5' exonuclease and 3'-phosphodiesterase, but not apurinic-apyrimidinic (AP) endonuclease, APEX2 activities. Has to be loaded onto DNA in order to be able to stimulate APEX2. Plays a key role in DNA damage response (DDR) by being conveniently positioned at the replication fork to coordinate DNA replication with DNA repair and DNA damage tolerance pathways. [PubMed: 24939902 Acts as a loading platform to recruit DDR proteins that allow completion of DNA replication after DNA damage and promote postreplication repair: Monoubiquitinated PCNA leads to recruitment of translesion (TLS) polymerases, while 'Lys-63'-linked polyubiquitination of PCNA is involved in error-free pathway and employs recombination mechanisms to synthesize across the lesion.] | |
| Protein Sequence | MFEARLVQGSILKKVLEALKDLINEACWDISSSGVNLQSMDSSHVSLVQLTLRSEGFDTYRCDRNLAMGVNLTSMSKILKCAGNEDIITLRAEDNADTLALVFEAPNQEKVSDYEMKLMDLDVEQLGIPEQEYSCVVKMPSGEFARICRDLSHIGDAVVISCAKDGVKFSASGELGNGNIKLSQTSNVDKEEEAVTIEMNEPVQLTFALRYLNFFTKATPLSSTVTLSMSADVPLVVEYKIADMGHLKYYLAPKIEDEEGS | |
| Overview of Protein Modification Sites with Functional and Structural Information | ||
|
|
||
* ASA = Accessible Surface Area
| Locations | Modification | Substrate Peptides & Secondary Structure |
ASA (%) | Reference | Orthologous Protein Cluster |
|---|---|---|---|---|---|
| 5 | Methylation | ---MFEARLVQGSIL ---CCCHHHHCHHHH | 28.35 | 115486671 | |
| 10 | Phosphorylation | EARLVQGSILKKVLE CHHHHCHHHHHHHHH | 13.99 | 24719451 | |
| 10 | O-linked_Glycosylation | EARLVQGSILKKVLE CHHHHCHHHHHHHHH | 13.99 | 23301498 | |
| 13 | Succinylation | LVQGSILKKVLEALK HHCHHHHHHHHHHHH | 38.88 | 23954790 | |
| 13 | Acetylation | LVQGSILKKVLEALK HHCHHHHHHHHHHHH | 38.88 | 23749302 | |
| 13 | Ubiquitination | LVQGSILKKVLEALK HHCHHHHHHHHHHHH | 38.88 | 23000965 | |
| 14 | Ubiquitination | VQGSILKKVLEALKD HCHHHHHHHHHHHHH | 48.91 | 23000965 | |
| 14 | Acetylation | VQGSILKKVLEALKD HCHHHHHHHHHHHHH | 48.91 | 19419956 | |
| 14 | 2-Hydroxyisobutyrylation | VQGSILKKVLEALKD HCHHHHHHHHHHHHH | 48.91 | - | |
| 20 | Ubiquitination | KKVLEALKDLINEAC HHHHHHHHHHHHHHH | 58.50 | PubMed | |
| 60 | Phosphorylation | RSEGFDTYRCDRNLA CCCCCCEEECCCCCC | 15.87 | - | |
| 60 | Nitration | RSEGFDTYRCDRNLA CCCCCCEEECCCCCC | 15.87 | - | |
| 61 | Methylation | SEGFDTYRCDRNLAM CCCCCEEECCCCCCC | 20.25 | 115486687 | |
| 68 | Sulfoxidation | RCDRNLAMGVNLTSM ECCCCCCCCCCHHHH | 7.49 | 21406390 | |
| 73 | Phosphorylation | LAMGVNLTSMSKILK CCCCCCHHHHHHHHH | 19.72 | 21406692 | |
| 74 | Phosphorylation | AMGVNLTSMSKILKC CCCCCHHHHHHHHHH | 24.99 | 21406692 | |
| 76 | Phosphorylation | GVNLTSMSKILKCAG CCCHHHHHHHHHHHC | 19.13 | 21406692 | |
| 77 | Malonylation | VNLTSMSKILKCAGN CCHHHHHHHHHHHCC | 43.34 | 26320211 | |
| 77 | Ubiquitination | VNLTSMSKILKCAGN CCHHHHHHHHHHHCC | 43.34 | 23000965 | |
| 77 | Acetylation | VNLTSMSKILKCAGN CCHHHHHHHHHHHCC | 43.34 | 19608861 | |
| 80 | Malonylation | TSMSKILKCAGNEDI HHHHHHHHHHCCCCE | 26.05 | 26320211 | |
| 80 | 2-Hydroxyisobutyrylation | TSMSKILKCAGNEDI HHHHHHHHHHCCCCE | 26.05 | - | |
| 80 | Ubiquitination | TSMSKILKCAGNEDI HHHHHHHHHHCCCCE | 26.05 | 23000965 | |
| 80 | Acetylation | TSMSKILKCAGNEDI HHHHHHHHHHCCCCE | 26.05 | 19608861 | |
| 81 | S-nitrosocysteine | SMSKILKCAGNEDII HHHHHHHHHCCCCEE | 5.41 | - | |
| 81 | Glutathionylation | SMSKILKCAGNEDII HHHHHHHHHCCCCEE | 5.41 | 22555962 | |
| 81 | S-nitrosylation | SMSKILKCAGNEDII HHHHHHHHHCCCCEE | 5.41 | 22178444 | |
| 110 | Ubiquitination | FEAPNQEKVSDYEMK EECCCCCCCCCHHEE | 36.96 | 21906983 | |
| 114 | Phosphorylation | NQEKVSDYEMKLMDL CCCCCCCHHEEECCC | 15.49 | 29116813 | |
| 117 | Ubiquitination | KVSDYEMKLMDLDVE CCCCHHEEECCCCHH | 28.81 | 21963094 | |
| 117 | Neddylation | KVSDYEMKLMDLDVE CCCCHHEEECCCCHH | 28.81 | 32015554 | |
| 119 | Sulfoxidation | SDYEMKLMDLDVEQL CCHHEEECCCCHHHH | 3.92 | 28465586 | |
| 133 | Phosphorylation | LGIPEQEYSCVVKMP HCCCCCEEEEEEECC | 13.68 | 29116813 | |
| 134 | Phosphorylation | GIPEQEYSCVVKMPS CCCCCEEEEEEECCC | 10.32 | 29116813 | |
| 135 | Glutathionylation | IPEQEYSCVVKMPSG CCCCEEEEEEECCCC | 3.90 | 22555962 | |
| 138 | Ubiquitination | QEYSCVVKMPSGEFA CEEEEEEECCCCHHH | 25.38 | 21963094 | |
| 139 | Sulfoxidation | EYSCVVKMPSGEFAR EEEEEEECCCCHHHH | 1.84 | 21406390 | |
| 146 | Methylation | MPSGEFARICRDLSH CCCCHHHHHHHHHHH | 33.58 | 115486679 | |
| 152 | Phosphorylation | ARICRDLSHIGDAVV HHHHHHHHHCCCEEE | 19.83 | 21712546 | |
| 161 | Phosphorylation | IGDAVVISCAKDGVK CCCEEEEEECCCCCE | 9.08 | 28258704 | |
| 162 | S-palmitoylation | GDAVVISCAKDGVKF CCEEEEEECCCCCEE | 3.61 | 26865113 | |
| 162 | S-nitrosocysteine | GDAVVISCAKDGVKF CCEEEEEECCCCCEE | 3.61 | - | |
| 162 | Glutathionylation | GDAVVISCAKDGVKF CCEEEEEECCCCCEE | 3.61 | 22555962 | |
| 162 | S-nitrosylation | GDAVVISCAKDGVKF CCEEEEEECCCCCEE | 3.61 | 22178444 | |
| 164 | Sumoylation | AVVISCAKDGVKFSA EEEEEECCCCCEEEE | 60.38 | 28112733 | |
| 164 | Acetylation | AVVISCAKDGVKFSA EEEEEECCCCCEEEE | 60.38 | 23954790 | |
| 164 | Sumoylation | AVVISCAKDGVKFSA EEEEEECCCCCEEEE | 60.38 | - | |
| 164 | 2-Hydroxyisobutyrylation | AVVISCAKDGVKFSA EEEEEECCCCCEEEE | 60.38 | - | |
| 164 | Ubiquitination | AVVISCAKDGVKFSA EEEEEECCCCCEEEE | 60.38 | 27667366 | |
| 164 | Neddylation | AVVISCAKDGVKFSA EEEEEECCCCCEEEE | 60.38 | 32015554 | |
| 168 | Acetylation | SCAKDGVKFSASGEL EECCCCCEEEECCCC | 38.85 | 26051181 | |
| 168 | Ubiquitination | SCAKDGVKFSASGEL EECCCCCEEEECCCC | 38.85 | 23000965 | |
| 170 | Phosphorylation | AKDGVKFSASGELGN CCCCCEEEECCCCCC | 18.79 | 28509920 | |
| 172 | Phosphorylation | DGVKFSASGELGNGN CCCEEEECCCCCCCC | 31.44 | 28509920 | |
| 181 | Ubiquitination | ELGNGNIKLSQTSNV CCCCCCEEEEECCCC | 46.19 | 22817900 | |
| 183 | Phosphorylation | GNGNIKLSQTSNVDK CCCCEEEEECCCCCC | 26.81 | 21406692 | |
| 185 | Phosphorylation | GNIKLSQTSNVDKEE CCEEEEECCCCCCCC | 20.92 | 21406692 | |
| 186 | Phosphorylation | NIKLSQTSNVDKEEE CEEEEECCCCCCCCC | 27.50 | 21406692 | |
| 190 | Ubiquitination | SQTSNVDKEEEAVTI EECCCCCCCCCCEEE | 63.84 | 33845483 | |
| 190 | Acetylation | SQTSNVDKEEEAVTI EECCCCCCCCCCEEE | 63.84 | 7367671 | |
| 199 | Sulfoxidation | EEAVTIEMNEPVQLT CCCEEEECCCCCHHH | 6.43 | 28183972 | |
| 210 | Methylation | VQLTFALRYLNFFTK CHHHHHHHHHHCCCC | 30.39 | 115486663 | |
| 211 | Phosphorylation | QLTFALRYLNFFTKA HHHHHHHHHHCCCCC | 13.57 | 17115032 | |
| 216 | Phosphorylation | LRYLNFFTKATPLSS HHHHHCCCCCCCCCC | 18.68 | 21712546 | |
| 217 | Ubiquitination | RYLNFFTKATPLSST HHHHCCCCCCCCCCE | 45.14 | 33845483 | |
| 217 | Acetylation | RYLNFFTKATPLSST HHHHCCCCCCCCCCE | 45.14 | 7367681 | |
| 219 | Phosphorylation | LNFFTKATPLSSTVT HHCCCCCCCCCCEEE | 26.73 | 26503514 | |
| 222 | Phosphorylation | FTKATPLSSTVTLSM CCCCCCCCCEEEEEE | 25.76 | 30576142 | |
| 223 | Phosphorylation | TKATPLSSTVTLSMS CCCCCCCCEEEEEEC | 34.28 | 30576142 | |
| 228 | Phosphorylation | LSSTVTLSMSADVPL CCCEEEEEECCCCCE | 11.00 | 26503514 | |
| 229 | Sulfoxidation | SSTVTLSMSADVPLV CCEEEEEECCCCCEE | 4.27 | 28183972 | |
| 230 | Phosphorylation | STVTLSMSADVPLVV CEEEEEECCCCCEEE | 20.24 | 26503514 | |
| 239 | Phosphorylation | DVPLVVEYKIADMGH CCCEEEEEEECCCCC | 8.97 | 26503514 | |
| 244 | Sulfoxidation | VEYKIADMGHLKYYL EEEEECCCCCCEEEE | 2.42 | 30846556 | |
| 248 | Acetylation | IADMGHLKYYLAPKI ECCCCCCEEEECCCC | 26.61 | 19608861 | |
| 248 | Ubiquitination | IADMGHLKYYLAPKI ECCCCCCEEEECCCC | 26.61 | 23000965 | |
| 248 | 2-Hydroxyisobutyrylation | IADMGHLKYYLAPKI ECCCCCCEEEECCCC | 26.61 | - | |
| 248 | Neddylation | IADMGHLKYYLAPKI ECCCCCCEEEECCCC | 26.61 | 32015554 | |
| 250 | Phosphorylation | DMGHLKYYLAPKIED CCCCCEEEECCCCCC | 8.52 | 17081983 | |
| 254 | Sumoylation | LKYYLAPKIEDEEGS CEEEECCCCCCCCCC | 53.79 | 28112733 | |
| 254 | Ubiquitination | LKYYLAPKIEDEEGS CEEEECCCCCCCCCC | 53.79 | 23000965 | |
| 254 | Sumoylation | LKYYLAPKIEDEEGS CEEEECCCCCCCCCC | 53.79 | - | |
| 254 | Acetylation | LKYYLAPKIEDEEGS CEEEECCCCCCCCCC | 53.79 | 26051181 | |
| 261 | Phosphorylation | KIEDEEGS------- CCCCCCCC------- | 40.09 | 22617229 |
| Modified Location | Modified Residue | Modification | Type of Upstream Proteins | Gene Name of Upstream Proteins | UniProt AC of Upstream Proteins | Sources |
|---|---|---|---|---|---|---|
| 60 | Y | Phosphorylation | Kinase | IGF1R | P08069 | PSP |
| 133 | Y | Phosphorylation | Kinase | IGF1R | P08069 | PSP |
| 211 | Y | Phosphorylation | Kinase | EGFR | P00533 | Uniprot |
| 250 | Y | Phosphorylation | Kinase | IGF1R | P08069 | PSP |
| - | K | Ubiquitination | E3 ubiquitin ligase | DTL | Q9NZJ0 | PMID:20129063 |
| - | K | Ubiquitination | E3 ubiquitin ligase | HUWE1 | Q7Z6Z7 | PMID:22203964 |
| - | K | Ubiquitination | E3 ubiquitin ligase | RNF8 | O76064 | PMID:18948756 |
| - | K | Ubiquitination | E3 ubiquitin ligase | RAD18 | Q9NS91 | PMID:12226657 |
| - | K | Ubiquitination | E3 ubiquitin ligase | HLTF | Q14527 | PMID:18719106 |
| - | K | Ubiquitination | E3 ubiquitin ligase | PAXIP1 | Q6ZW49 | PMID:22199232 |
| - | K | Ubiquitination | E3 ubiquitin ligase | SHPRH | Q149N8 | PMID:17130289 |
* Distance = the distance between SAP position and PTM sites.
| Modified Location | Modification | Variant Position (Distance <= 10) |
Residue Change | SAP | Related Disease | Reference |
|---|---|---|---|---|---|---|
Oops, there are no SNP-PTM records of PCNA_HUMAN !! | ||||||
| Kegg Disease | ||||||
|---|---|---|---|---|---|---|
| There are no disease associations of PTM sites. | ||||||
| OMIM Disease | ||||||
| 615919 | Ataxia-telangiectasia-like disorder 2 (ATLD2) | |||||
| Kegg Drug | ||||||
| There are no disease associations of PTM sites. | ||||||
| DrugBank | ||||||
| There are no disease associations of PTM sites. | ||||||
loading...
| Acetylation | |
| Reference | PubMed |
| "Lysine acetylation targets protein complexes and co-regulates majorcellular functions."; Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.,Olsen J.V., Mann M.; Science 325:834-840(2009). Cited for: ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-77; LYS-80 AND LYS-248, ANDMASS SPECTROMETRY. | |
| Phosphorylation | |
| Reference | PubMed |
| "Tyrosine phosphorylation controls PCNA function through proteinstability."; Wang S.C., Nakajima Y., Yu Y.L., Xia W., Chen C.T., Yang C.C.,McIntush E.W., Li L.Y., Hawke D.H., Kobayashi R., Hung M.C.; Nat. Cell Biol. 8:1359-1368(2006). Cited for: PHOSPHORYLATION AT TYR-211 BY EGFR, MUTAGENESIS OF TYR-211, ANDINTERACTION WITH EGFR. | |
| Ubiquitylation | |
| Reference | PubMed |
| "Human SHPRH is a ubiquitin ligase for Mms2-Ubc13-dependentpolyubiquitylation of proliferating cell nuclear antigen."; Unk I., Hajdu I., Fatyol K., Szakal B., Blastyak A., Bermudez V.,Hurwitz J., Prakash L., Prakash S., Haracska L.; Proc. Natl. Acad. Sci. U.S.A. 103:18107-18112(2006). Cited for: UBIQUITINATION AT LYS-164, AND MUTAGENESIS OF LYS-164. | |
| "Human SHPRH suppresses genomic instability through proliferating cellnuclear antigen polyubiquitination."; Motegi A., Sood R., Moinova H., Markowitz S.D., Liu P.P., Myung K.; J. Cell Biol. 175:703-708(2006). Cited for: INTERACTION WITH SHPRH, UBIQUITINATION AT LYS-164, AND MUTAGENESIS OFLYS-164. | |